MedTrace Logo

A Study to Compare Pharmacokinetic Parameters and Safety Profiles Between AD-109 and AD-1091

NCT05128591 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2022-03-08

No results posted yet for this study

Summary

Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-109 in healthy male subjects.

Conditions

  • Embolism and Thrombosis

Interventions

DRUG

Rivaroxaban 18mg Oral Tablet

AD-109 (Rivaroxaban 18mg) Oral Tablet

DRUG

Rivaroxaban 20 MG Oral Tablet

AD-1091 (Rivaroxaban 20mg) Oral Tablet

Sponsors & Collaborators

  • Addpharma Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-09
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05128591 on ClinicalTrials.gov